OmniCyte Awarded NSF Phase II SBIR Grant to Develop a Next Generation COVID Vaccine Using Its Immune Activating Platform
OmniCyte announced that it has been awarded a Phase II SBIR grant for $997,689 from the NSF to further develop its Novel Platform Based Vaccine for SARS-CoV-2. BRANFORD, CONNECTICUT, USA, March 21, 2024 /EINPresswire.com/ -- OmniCyte, LLC is …